The first diagnostic test to classify cancers by differences in microRNAs–small pieces of RNA that regulate genes–will soon be on the market. The test distinguishes two types of lung cancer and should help doctors tailor treatments to their patients’ needs. Scientists say that tests based on microRNA profiles could prove more sensitive and reliable than existing methods, whose accuracy depends heavily on the judgment of the people analyzing them.
Product: MicroRNA test for lung cancer
Cost: Comparable to that of other molecular tests for cancer, which are priced at around $3,000 to $3,500
Company: Rosetta Genomics
Other products in this section:
Subscribe to Continue Reading
Uh oh–you've read all of your free articles for this month.
How Data Mining Facebook Messages Can Reveal Substance Abusers
Substance abuse changes people’s patterns of behavior, and this is detectable in their social media messages, say researchers.
Drug Is First to Treat Cancer Based on Genetics, Not Location
A change in how cancer is treated means more people will benefit from immunotherapy.
Microsoft Has a Plan to Add DNA Data Storage to Its Cloud
Tech companies think biology may solve a looming data storage problem.